(Adds GSK-Vir statement)
April 15 (Reuters) - The European Medicines Agency said on Thursday it is reviewing available data on the use of GlaxoSmithKline's monoclonal antibody to treat COVID-19 patients.
The agency said its review of VIR-7831, which GSK is developing with Vir Biotechnology Inc, will include data from a study comparing its effect with that of a placebo in patients with mild to moderate COVID-19 who were at high risk of progressing to a more severe condition. (https://bit.ly/3n0spGx)
While a more comprehensive rolling review is expected to start at a later time, the agency said the current review will provide European Union-wide recommendations for national authorities who may take decisions on early use of the medicine.
The companies reported in March that VIR-7831 reduced the risk of hospitalisation and deaths among patients by 85%, based on interim data from a study.
VIR-7831 has not been granted a marketing authorisation anywhere in the world. The companies said in a statement on Thursday they planned to submit a full marketing authorisation application to the EMA, and talks with global regulators were on to make VIR-7831 available to patients with COVID-19.
In late March, the companies filed an application to U.S. regulators for emergency use authorization of VIR-7831 to treat early-stage COVID-19 infections.
The United States has already recommended similar therapies from Eli Lilly and Co and Regeneron Pharmaceuticals Inc .
European health regulators are reviewing treatments from this class of medicines called monoclonal antibodies, which are synthetically manufactured copies of the human body's natural infection-fighting proteins and are already being used to treat some types of cancers.
GSK and Vir announced a partnership in 2020 to research COVID-19 treatments, and earlier this year said they will expand that partnership to develop monoclonal antibody treatments for influenza and other respiratory illnesses. (Reporting by Vishwadha Chander in Bengaluru; Editing by Bernard Orr and David Evans)